Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
The trial reportedly showed some benefit with no obvious harm
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B
Metabolics obesity drug - phase 2B clinical trial results: trial results do not support commercial viability of obesity project: programme is terminated [ASX Announcement]
However, this remains challenging for many obese individuals
Physiology 20:232238
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unapproved by the MHRA, EMA, or FDA for routine clinical use
US$ 27.31
US$ 29.83
US$ 29.57
US$ 28.16
US$ 20.64
US$ 29.86
US$ 22.38
US$ 25.80
